API | iloperidone

iloperidone (fanapt) Report issue

Small molecule Approved ^FDA

AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW

Iloperidone, also known as Fanapt, Fanapta, and previously known as Zomaril, is an atypical antipsychotic for the treatment of schizophrenia. Iloperidone shows high affinity and maximal receptor occupancy for dopamine D2 receptors in the caudate nucleus and putamen of the brains of schizophrenic patients. The improvement in cognition is attributed to iloperidone's high affinity for α adrenergic receptors. Iloperidone also binds with high affinity to serotonin 5-HT2a and dopamine 3 receptors. Iloperidone binds with moderate affinity to dopamine D4, serotonin 5-HT6 and 5-HT7, and norepinephrine NEα1 receptors. Furthermore, iloperidone binds with weak affinity to serotonin 5-HT1A, dopamine D1, and histamine H1 receptors. Iloperidone is indicated for the treatment of acute schizophrenia. ^NCATS

Chemistry

SMILES: COC1=CC(=CC=C1OCCCN2CCC(CC2)C3=NOC4=C3C=CC(F)=C4)C(C)=O
InChIKey: XMXHEBAFVSFQEX-UHFFFAOYSA-N
Mol. Mass: 426.4806
ALogP: 4.83 Partition coefficient
ChEMBL Molecule:
iloperidone

More Chemistry

Pharmacology

Mechanisms of Action:
- D(2) dopamine receptor (Homo sapiens) ^UniProt
- 5-hydroxytryptamine receptor 2A (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: Yes
Availability: Prescription Only
Delivery Methods: Oral
Pro Drug: No

Drug Pricing (per unit)

United States

$14.0040 - $47.0595

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Organizations (43)

Research & Development (38)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (6)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (24)

Approved Indications (1)

Schizophrenia

Experimental Indications - Clinical Trial Phases 1-4 (24)

Allergy and Immunology (Phase 3)

Alzheimer Disease (Phase 3)

Arthritis, Rheumatoid (Phase 2)

Bipolar Disorder (Phase 4)

Depressive Disorder, Major (Phase 4)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Phase 3)

Drug Evaluation (Phase 2)

Drugs, Investigational (Phase 2)

General Surgery (Phase 3)

Gingivitis (Phase 2)

Healthy Volunteers (Phase 4)

Keratosis, Actinic (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Liver Diseases (Phase 1)

Parkinson Disease (Phase 2)

Pharmacological and Toxicological Phenomena (Phase 1)

Psychotic Disorders (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Rhinitis, Allergic (Phase 3)

Rhinitis, Allergic, Perennial (Phase 3)

Schizophrenia ()

Stress Disorders, Post-Traumatic (Phase 2)

Therapeutic Equivalency (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 36
# of Trial Organizations: 38

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue